Article Figures & Data
Figures
- FIG. 1.
Immunofluorescent staining patterns produced by four different ANCA assays, both on ethanol- and on formalin-fixed human neutrophils, for two different patients. Atypical P-ANCA present as broad, nonhomogeneous rim-like staining of the nuclear periphery on an ethanol slide and show little or no perinuclear or cytoplasmic staining on a formalin slide. P-ANCA (perinuclear staining) show a fine, homogeneous fluorescent staining of the perinuclear cytoplasm on an ethanol slide and diffusely label the cytoplasm (i.e., convert to C-ANCA) on a formalin slide. C-ANCA (cytoplasmic staining) yield a coarse, speckled cytoplasmic fluorescent pattern with accentuated fluorescence between the nuclear lobes on an ethanol slide, and this pattern becomes more pronounced on a formalin slide. (A) All four ANCA assays show atypical P-ANCA patterns for the serum sample of UC patient 104. (B) The four ANCA assays show distinct ANCA patterns for the serum sample of UC patient 95. Magnification, ×40.
Tables
- TABLE 1.
Clinical data for UC and CD patients and non-IBD gastrointestinal-disease controls
Group and characteristic Value for group UC patients (n = 96) Males/females 46/50 Age (yr) (mean ± SD) 39.8 ± 14.9 Disease location (%) Left-sided colitis 67.4 Extensive 23.1 Proctitis 9.5 Surgery (%) 5.2 Extraintestinal manifestations (%) 28.4 CD patients (n = 108) Males/females 43/65 Age (yr) (mean ± SD) 34.0 ± 12.2 Disease behavior (%) Nonstricturing, nonpenetrating (B1) 39.8 Stricturing (B2) 26.7 Penetrating (B3) 33.5 Disease location (%) Terminal ileum (L1) 22.8 Colon (L2) 25.1 Ileocolon (L3) 51.3 Upper gastrointestinal tract (L4) 0.9 Perianal disease (%) 29.2 Surgery (%) 40.9 Extraintestinal manifestations (%) 41.7 Non-IBD gastrointestinal-disease controls Irritable bowel syndrome/diverticulosis patients (n = 64) Males/females 30/34 Age (yr) (mean ± SD) 38.2 ± 15.1 Celiac disease patients (n = 96) Males/females 23/73 Age (yr) (mean ± SD) 35.7 ± 17.4 - TABLE 2.
Results of the interassay study with four ANCA assays
Patient group and ANCA pattern No. (%) of patients with ANCA patterns observed by the following assay: Inova Immco Euroimmun Immuno Concepts ANA-negative UC patients (n = 79) Total ANCA 43 (54.4) 40 (50.6) 31 (39.2) 30 (38.0) Atypical P-ANCA 34 (43.0) 5 (6.3) 23 (29.1) 23 (29.1) P-ANCA 6 (7.6) 30 (38.0) 8 (10.1) 4 (5.1) C-ANCA 3 (3.8) 5 (6.3) 0 (0.0) 3 (3.8) ANA-negative CD patients (n = 99) Total ANCA 18 (18.2) 23 (23.2) 11 (11.1) 11 (11.1) Atypical P-ANCA 16 (16.2) 9 (9.1) 8 (8.1) 9 (9.1) P-ANCA 2 (2.0) 10 (10.1) 3 (3.0) 1 (1.0) C-ANCA 0 (0.0) 4 (4.0) 0 (0.0) 1 (1.0) Non-IBD gastrointestinal-disease control groups Irritable bowel syndrome/ diverticulosis patients without inflammation (n = 64) Total ANCA 2 (3.1) 3 (4.7) Atypical P-ANCA 1 (1.6) 1 (1.6) P-ANCA 1 (1.6) 2 (3.1) C-ANCA 0 (0.0) 0 (0.0) Celiac disease patients (n = 96) Total ANCA 5 (5.2) 4 (4.2) Atypical P-ANCA 2 (2.1) 2 (2.1) P-ANCA 3 (3.1) 2 (2.1) C-ANCA 0 (0.0) 0 (0.0) - TABLE 3.
Concordance between four different immunofluorescent ANCA tests with regard to atypical P-ANCA
Test Concordancea with the following assay: Inova Immco Euroimmun Immuno Concepts Inova 1 Immco 0.11 1 Euroimmun 0.39 0.03 1 Immuno Concepts 0.35 0.12 0.29 1 ↵a Agreement was characterized by the κ coefficient.
- TABLE 4.
Distribution of the immunofluorescent patterns detected by different assays in IBD patients with antibodies against lactoferrin, BPI, or lysozyme
Test No. of casesa Atypical P-ANCA Typical P-ANCA C-ANCA Negative Immco 7 14 6 4 Inova 16 4 0 11 Euroimmun 9 4 0 18 Immuno Concepts 9 1 1 20 ↵a A total of 31 patients were tested. Four patients had antibodies against both lactoferrin and BPI, and six patients had antibodies against MPO or PR3 as well.
